Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours (Q37287413)
Jump to navigation
Jump to search
scientific article published on 30 June 2009
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours |
scientific article published on 30 June 2009 |
Statements
1 reference
Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours (English)
1 reference
V Gregorc
1 reference
A Santoro
1 reference
E Bennicelli
1 reference
C J A Punt
1 reference
G Citterio
1 reference
J N H Timmer-Bonte
1 reference
F Caligaris Cappio
1 reference
A Lambiase
1 reference
C Bordignon
1 reference
C M L van Herpen
1 reference
30 June 2009
1 reference
1 reference
219-224
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference